Minerva Neurosciences (NERV) Q3 2025 earnings summary

Executive summary

• Focused on developing roluperidone for negative symptoms in schizophrenia, with no commercial products or revenue to date.

• FDA required an additional confirmatory Phase 3 trial for roluperidone after a Complete Response Letter in February 2024; company aligned with FDA on trial design and aims for NDA resubmission and potential US launch.

• Completed a $200 million private placement in October 2025, receiving $80 million upfront and potential for up to $120 million more if warrants are exercised, to fund the Phase 3 trial, NDA resubmission, and commercial launch.

Financial highlights

• Net loss of $2.7 million for Q3 2025, compared to net income of $22.5 million in Q3 2024, due to a one-time $26.6 million other income in 2024.

• Net loss of $9.8 million for the nine months ended September 30, 2025, versus net income of $5.7 million for the same period in 2024.

• R&D expenses decreased to $0.9 million in Q3 2025 from $1.9 million in Q3 2024; nine-month R&D expense was $3.6 million, down from $9.9 million year-over-year.

• G&A expenses fell to $1.9 million in Q3 2025 from $2.5 million in Q3 2024; nine-month G&A expense was $6.5 million, down from $7.4 million year-over-year.

• Cash, cash equivalents, and restricted cash totaled $12.4 million as of September 30, 2025, down from $21.5 million at December 31, 2024.

Outlook and guidance

• Proceeds from the private placement are expected to fund operations, the Phase 3 trial, NDA resubmission, and commercial launch preparations for at least 12 months from the financial statement issuance date.

• Anticipates continued operating losses and negative cash flows as development and regulatory activities progress, with expectation of increased R&D, clinical, and administrative expenses.